2024 annual financial data
Immunovant 2024 Operating margin
Immunovant 2024 operating margin with verified reported values.
Direct answer
Operating margin was Not calculable.
Operating income was -270,209,000 USD and net income was -259,336,000 USD.
Operating cash flow was -214,227,000 USD.
Get free Immunovant email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -270,209,000 USD
- Net income
- -259,336,000 USD
- Operating cash flow
- -214,227,000 USD